Dalton W S, Grogan T M, Rybski J A, Scheper R J, Richter L, Kailey J, Broxterman H J, Pinedo H M, Salmon S E
Department of Medicine, Arizona Cancer Center, University of Arizona, Tucson 85724.
Blood. 1989 Feb 15;73(3):747-52.
Using several multiple drug-resistant human myeloma cell lines as standards, we developed an immunohistochemical staining technique and means of quantitating P-glycoprotein in individual myeloma cells. The level of staining intensity for P-glycoprotein in individual myeloma cells was quantitated by measuring the average optical density of each cell with a microscopic computerized cell analysis system. Using this system, we observed that the level of P-glycoprotein for individual cells within a cell population of known drug sensitivity was very homogeneous (coefficient of variation less than or equal to 13%). Analysis of cell lines with gradually increasing levels of multidrug resistance (8226/S, 8226/Dox6 and 8226/Dox40) demonstrated a close association between the level of resistance to doxorubicin, defined by the mean lethal dose (D0) and the amount of P-glycoprotein on individual cells determined by the optical density (r = 0.82, P less than 0.0005). Intracellular doxorubicin (DOX) accumulation in the individual cell lines was inversely related to the level of drug resistance expressed as D0. P-glycoprotein was also detected in the marrow-derived myeloma cells of patients with drug refractory disease using immunohistochemical staining. The amount of P-glycoprotein in the cells of one patient was directly compared to the amount found in the simultaneously stained standard cell lines (8226/Dox6 and 8226/Dox40) by comparing the optical densities for individual cells. Using this immunohistochemical technique to detect and quantitate P-glycoprotein in patient myeloma cells and comparing it to standard multidrug resistant myeloma cell lines may be of value in determining the contribution of P-glycoprotein to clinical drug resistance in patients with multiple myeloma.
以几种多重耐药的人骨髓瘤细胞系作为标准,我们开发了一种免疫组织化学染色技术以及定量单个骨髓瘤细胞中P - 糖蛋白的方法。通过使用显微计算机化细胞分析系统测量每个细胞的平均光密度,来定量单个骨髓瘤细胞中P - 糖蛋白的染色强度水平。使用该系统,我们观察到在已知药物敏感性的细胞群体中,单个细胞的P - 糖蛋白水平非常均一(变异系数小于或等于13%)。对多药耐药水平逐渐增加的细胞系(8226/S、8226/Dox6和8226/Dox40)的分析表明,由平均致死剂量(D0)定义的对阿霉素的耐药水平与通过光密度测定的单个细胞上P - 糖蛋白的量之间存在密切关联(r = 0.82,P小于0.0005)。单个细胞系中细胞内阿霉素(DOX)的积累与以D0表示的耐药水平呈负相关。使用免疫组织化学染色在药物难治性疾病患者的骨髓来源骨髓瘤细胞中也检测到了P - 糖蛋白。通过比较单个细胞的光密度,将一名患者细胞中的P - 糖蛋白量与同时染色的标准细胞系(8226/Dox6和8226/Dox40)中发现的量进行直接比较。使用这种免疫组织化学技术检测和定量患者骨髓瘤细胞中的P - 糖蛋白,并将其与标准多药耐药骨髓瘤细胞系进行比较,可能对确定P - 糖蛋白在多发性骨髓瘤患者临床耐药中的作用有价值。